Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Receivables - Net: 2014-2025

Historic Receivables - Net for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $579.3 million.

  • Surgery Partners' Receivables - Net rose 670.47% to $579.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $579.3 million, marking a year-over-year increase of 670.47%. This contributed to the annual value of $579.1 million for FY2024, which is 1666.0% up from last year.
  • As of Q3 2025, Surgery Partners' Receivables - Net stood at $579.3 million, which was up 670.47% from $563.1 million recorded in Q2 2025.
  • Surgery Partners' Receivables - Net's 5-year high stood at $579.3 million during Q3 2025, with a 5-year trough of $367.0 million in Q1 2021.
  • Its 5-year average for Receivables - Net is $472.8 million, with a median of $456.3 million in 2022.
  • As far as peak fluctuations go, Surgery Partners' Receivables - Net soared by 2058.54% in 2021, and later soared by 606.69% in 2022.
  • Over the past 5 years, Surgery Partners' Receivables - Net (Quarter) stood at $430.2 million in 2021, then rose by 6.07% to $456.3 million in 2022, then rose by 8.79% to $496.4 million in 2023, then rose by 16.66% to $579.1 million in 2024, then rose by 0.03% to $579.3 million in 2025.
  • Its Receivables - Net stands at $579.3 million for Q3 2025, versus $563.1 million for Q2 2025 and $570.6 million for Q1 2025.